5,005
edits
No edit summary |
|||
Line 42: | Line 42: | ||
==Sleep Medicine Program== | ==Sleep Medicine Program== | ||
* W8MD’s [[sleep medicine]] program provides state-of-the-art technology to diagnose and treat over 80 different sleep disorders, including [[sleep apnea]], [[narcolepsy]], [[restless legs syndrome]], and [[insomnia]]. With convenient home sleep studies or in-lab sleep diagnostic studies, patients can receive an accurate diagnosis and effective treatment. | * W8MD’s [[sleep medicine]] program provides state-of-the-art technology to diagnose and treat over 80 different sleep disorders, including [[sleep apnea]], [[narcolepsy]], [[restless legs syndrome]], and [[insomnia]]. With convenient home sleep studies or in-lab sleep diagnostic studies, patients can receive an accurate diagnosis and effective treatment. | ||
==Nutrition== | ==Nutrition== | ||
Line 51: | Line 49: | ||
|} | |} | ||
<h2 style="margin:0;background-color:#dfefdf;font-size:120%;font-weight:bold;border:1px solid #defbfa;text-align:left;color:#000;padding:0.2em 0.4em;">'''Weight loss news'''</h2> | <h2 style="margin:0;background-color:#dfefdf;font-size:120%;font-weight:bold;border:1px solid #defbfa;text-align:left;color:#000;padding:0.2em 0.4em;">'''Weight loss news'''</h2> | ||
In October 2022, the Food and Drug Administration (FDA) granted Mounjaro, a diabetes drug, a fast-track designation for weight loss, leading to speculation that it will be approved for weight loss use this year due to its promising results in clinical trials. | In October 2022, the Food and Drug Administration (FDA) granted Mounjaro, a diabetes drug, a fast-track designation for weight loss, leading to speculation that it will be approved for weight loss use this year due to its promising results in clinical trials. | ||
[[File:Weight-loss-success-stories.jpeg|thumb|Weight loss success stories]] | [[File:Weight-loss-success-stories.jpeg|thumb|Weight loss success stories]] | ||
==Mounjaro weight loss results== | ==Zepbound / Mounjaro (Tirzepatide) weight loss results== | ||
[[Mounjaro]] | [[Tirzepatide]], available as [[Zepbound]] and [[Mounjaro]], is a weekly injection that helps control blood sugar levels and was approved for use in treating type 2 diabetes by the FDA in May 2022. Distinguished from drugs such as [[Ozempic]] and [[Wegovy]] both of which have [[Semaglutide]], [[Zepbound]], [[Mounjaro]] with active ingredient of [[Tirzepatide]] is a combination of a glucagon-like peptide-1 (GLP-1) receptor agonist, used for diabetes and weight loss treatment, and a glucose-dependent insulinotropic polypeptide (GIP), a hormone that aids insulin release after eating. | ||
==Wegovy injections== | |||
==Wegovy (Semaglutide) injections== | |||
Although it has yet to be approved by the FDA for [[weight loss]], some doctors, including '''W8MD weight loss physicians''', prescribe it for off-label use to help with weight loss in patients without type 2 diabetes. In fact, Mounjaro became so popular that it was listed by the FDA as one of nearly 200 drugs experiencing a supply shortage, along with [[Wegovy]], [[Ozempic]] (semaglutide), and [[Trulicity]] (dulaglutide), which are sometimes prescribed for off-label [[weight loss]] use. [[Mounjaro|Learn more...]] | Although it has yet to be approved by the FDA for [[weight loss]], some doctors, including '''W8MD weight loss physicians''', prescribe it for off-label use to help with weight loss in patients without type 2 diabetes. In fact, Mounjaro became so popular that it was listed by the FDA as one of nearly 200 drugs experiencing a supply shortage, along with [[Wegovy]], [[Ozempic]] (semaglutide), and [[Trulicity]] (dulaglutide), which are sometimes prescribed for off-label [[weight loss]] use. [[Mounjaro|Learn more...]] | ||
[[File:W8md-protein-bar.jpeg|thumb|Weight loss supplements]] | [[File:W8md-protein-bar.jpeg|thumb|Weight loss supplements]] |